Portola Pharmaceuticals Email Format

Pharmaceutical ManufacturingCalifornia, United States201-500 Employees

We are focused on the discovery, development and commercialization of novel therapeutics that could significantly advance the fields of thrombosis and other hematologic conditions.
 
The Company's first two commercialized products are Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], marketed in Europe as Ondexxya® (andexanet alfa), and Bevyxxa® (betrixaban). The company also is advancing cerdulatinib, an investigational SYK/JAK inhibitor being developed for the treatment of hematologic cancers.
 
We are continuing to explore new discoveries that impact how serious blood-related disorders are treated and expanding the potential impact of our existing portfolio of medicines.

✕

Access Insights for Portola Pharmaceuticals and Millions of Other Companies

Sign up for full access to Portola Pharmaceuticals information.

Continue with GoogleContinue with Microsoft

No credit card needed

OR

Work email

Create AccountBy creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.

Sign up for free to view info

Company overview Employee directory